

University of Groningen

A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment

Daskapan, Alper

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Daskapan, A. (2018). *A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment*. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Samenvatting

Dankwoord

Curriculum Vitae

Publication list

1. **Daskapan A**, Stienstra Y, Akkerman OW, de Lange WC, Kosterink JG, van der Werf TS, et al. The Never Ending Struggle Against Development of Drug Resistance. *Clin Infect Dis* 2015 Jul 1;61(1):137-138.
2. **Daskapan A**, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, et al. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. *Eur Respir J* 2015 Feb;45(2):569-571.
3. **Daskapan A**, Dijkema D, de Weerd DA, Bierman WFW, Kosterink JGW, van der Werf TS, et al. Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. *Br J Clin Pharmacol* 2017 Oct;83(10):2325-2329.
4. **Daskapan A**, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, et al. Risk factors contributing to a low darunavir plasma concentration. *Br J Clin Pharmacol* 2018 Mar;84(3):456-461.
5. Klis S, **Daskapan A**, Akkerman OW, Alffenaar JW, Stienstra Y. Raltegravir and rifampicin in patients with HIV and tuberculosis. *Lancet Infect Dis* 2014 Nov;14(11):1046-1047.
6. Van't Boveneind-Vrubleuskaya N, **Daskapan A**, Kosterink JG, van der Werf TS, van den Hof S, Alffenaar JC. Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. *PLoS One* 2016 Nov 10;11(11):e0166030.
7. **Daskapan A**, van Hateren K, Stienstra Y, Kosterink J, van der Werf T, Touw D et al. Development and Validation of a Bioanalytical Method for the Simultaneous Determination of 14 Antiretroviral Drugs using Liquid Chromatography-Tandem Mass Spectrometry. *Journal of Applied Bioanalysis*. 2018;4(2):37-50.



